Oakbrook Investments LLC bought a new stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the first quarter, Holdings Channel reports. The firm bought 6,125 shares of the biopharmaceutical company’s stock, valued at approximately $2,373,000.

A number of other large investors have also recently bought and sold shares of the company. WFG Advisors LP raised its stake in Regeneron Pharmaceuticals by 12,358.3% in the fourth quarter. WFG Advisors LP now owns 7,475 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 7,415 shares during the period. Alpha Windward LLC raised its stake in Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares during the period. Live Your Vision LLC purchased a new stake in Regeneron Pharmaceuticals during the third quarter valued at $157,000. Blenheim Capital Management BV purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $160,000. Finally, March Altus Capital Management LP purchased a new stake in Regeneron Pharmaceuticals during the third quarter valued at $201,000. Institutional investors own 68.83% of the company’s stock.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) traded up 1.47% on Thursday, hitting $376.40. 767,935 shares of the stock were exchanged. Regeneron Pharmaceuticals Inc has a 1-year low of $325.35 and a 1-year high of $452.96. The stock has a market cap of $39.70 billion, a price-to-earnings ratio of 48.89 and a beta of 1.44. The stock’s 50-day moving average is $379.53 and its 200-day moving average is $375.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, February 9th. The biopharmaceutical company reported $3.04 EPS for the quarter, topping the consensus estimate of $3.03 by $0.01. The firm had revenue of $1.23 billion for the quarter, compared to the consensus estimate of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 18.10% and a return on equity of 22.51%. The business’s revenue was up 11.7% compared to the same quarter last year. During the same period last year, the firm posted $2.83 earnings per share. Analysts forecast that Regeneron Pharmaceuticals Inc will post $12.92 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/oakbrook-investments-llc-buys-new-stake-in-regeneron-pharmaceuticals-inc-regn/1205693.html.

Several equities research analysts have weighed in on the stock. Leerink Swann set a $448.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, February 11th. Robert W. Baird reiterated a “neutral” rating and issued a $369.00 target price (down from $379.00) on shares of Regeneron Pharmaceuticals in a report on Sunday, January 8th. Morgan Stanley set a $370.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, January 9th. Credit Suisse Group AG reiterated a “buy” rating and issued a $485.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, February 10th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $598.00 target price (down from $626.00) on shares of Regeneron Pharmaceuticals in a report on Friday, January 6th. Fourteen research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $432.97.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, March 29th. The shares were sold at an average price of $400.00, for a total transaction of $400,000.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $400,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 10.40% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

5 Day Chart for NASDAQ:REGN

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.